A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions

Trigeminal Neuralgia

Interventions

DRUG

CNV1014802

CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.

DRUG

Placebo

Double-blind placebo comparator for 28 days.

Trial Locations (1)

Professor Joanna Zakrzewska, London